Skip to main content

Quality of Life Affected for a Majority of Patients With TD

June 02, 2020

Newly released data from the RE-KINECT real-world screening study suggest the involuntary movements associated with tardive dyskinesia (TD) reduce the health-related quality of life for many patients.

The data were released by Neurocrine Biosciences Inc. and published in the Journal of Clinical Psychopharmacology.

Among the 739 patients in the study who had been confirmed by a clinician to have TD , three-quarters said they have felt self-conscious or embarrassed about involuntary and uncontrollable movements.

About 40% of study participants with possible TD reported that involuntary movements had “some” or “a lot” of impact on their ability to continue usual activities, such as talking and socializing.

Meta-Analysis Supports Use of VMAT2 Inhibitors for Tardive Dyskinesia

"The real-world data from the RE-KINECT study are valuable for informing treatment decisions in clinical practice and demonstrate the importance of assessing the impact of involuntary movements from possible tardive dyskinesia on quality of life and daily functioning," said Stanley N. Caroff, MD, professor of psychiatry at the University of Pennsylvania Perelman School of Medicine and the Corporal Michael J. Crescenz VA Medical Center in Philadelphia.

It is estimated that TD, which is associated with the prolonged use of antipsychotics, affects at least 500,000 people in the United States, according to a statement from Neurocrine.

“These data support the continued need to raise awareness of involuntary movements from possible tardive dyskinesia and the importance of properly screening, diagnosing, and helping to relieve the suffering that many of these patients are experiencing,” Neurocrine chief medical officer Eiry W. Roberts, MD, said.

—Terri Airov


Neurocrine Biosciences announces new data published from the largest real-world screening study, RE-KINECT, demonstrating that movements consistent with tardive dyskinesia occur frequently and can reduce quality of life in patients with psychiatric disorders [press release]. San Diego, CA: Neurocrine Biosciences; May 7, 2020.

Back to Top